{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T03:52:36Z","timestamp":1769917956461,"version":"3.49.0"},"reference-count":30,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T00:00:00Z","timestamp":1582156800000},"content-version":"vor","delay-in-days":19,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Management of chronic hepatitis B (CHB) is still considered a challenge in clinical practice. Patients must be carefully evaluated before starting therapy. This includes virology and laboratory assessments, an estimation of fibrosis by invasive and\/or noninvasive methods, and an estimation of the risk of hepatocellular carcinoma (HCC). Nucleos(t)ide analogues (NAs) with a high barrier to resistance (tenofovir disoproxil fumarate [TDF], entecavir [ETV] and tenofovir alafenamide [TAF]) are the most frequently used treatments because of their good long\u2010term efficacy and tolerability. None of these options has been shown to be more effective than the other, but certain factors should be considered when selecting the best therapy for specific populations. Most patients achieve a virological and biochemical response to these agents, with a low rate of emerging resistance during long\u2010term treatment. However, the rate of hepatitis B surface antigen (HBsAg) loss is low and in most cases NAs therapy is lifelong. Safety concerns for long\u2010term NA use have become a priority in the management of CHB, in particular, the risk of impaired kidney function and bone marrow density loss described with TDF regimens. The risk of HCC is not completely eliminated by NAs. Thus, patients at higher risk should be identified and provided with appropriate surveillance.<\/jats:p>","DOI":"10.1111\/liv.14367","type":"journal-article","created":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T10:06:36Z","timestamp":1582193196000},"page":"15-21","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Optimal management of chronic hepatitis B patients receiving nucleos(t)ide analogues"],"prefix":"10.1111","volume":"40","author":[{"given":"Maria","family":"Buti","sequence":"first","affiliation":[{"name":"Liver Unit, Department of Internal Medicine Hospital Universitari Vall d\u2019Hebron Barcelona Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBERehd) Instituto de Salud Carlos III Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8160-9613","authenticated-orcid":false,"given":"Luisa","family":"Roade","sequence":"additional","affiliation":[{"name":"Liver Unit, Department of Internal Medicine Hospital Universitari Vall d\u2019Hebron Barcelona Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBERehd) Instituto de Salud Carlos III Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar","family":"Riveiro\u2010Barciela","sequence":"additional","affiliation":[{"name":"Liver Unit, Department of Internal Medicine Hospital Universitari Vall d\u2019Hebron Barcelona Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBERehd) Instituto de Salud Carlos III Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Esteban","sequence":"additional","affiliation":[{"name":"Liver Unit, Department of Internal Medicine Hospital Universitari Vall d\u2019Hebron Barcelona Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBERehd) Instituto de Salud Carlos III Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,2,20]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)30204-3"},{"issue":"67","key":"e_1_2_9_3_1","first-page":"370","article-title":"EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"2017","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J Hepatol"},{"key":"e_1_2_9_4_1","article-title":"Role of biomarkers in guiding cure of viral hepatitis B","author":"Buti M","year":"2019","journal-title":"Semin Liver Dis"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30087-1"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13053"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13641"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14155"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-019-1126-1"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61425-1"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.06.006"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13253"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0576"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12971"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5735-9"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.11.039"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.5009\/gnl16484"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw380"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27182"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.5604\/01.3001.0012.7918"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2018.00016"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(18)30002-5"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15188"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.06.009"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.02.006"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14241"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0618-8278(19)30168-9"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.07.019"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11030425"},{"key":"e_1_2_9_30_1","doi-asserted-by":"crossref","unstructured":"LoglioA RoadeL BorghiM et al.Validation of the Easl 2017 clinical practice guidelines criteria for switching HBV patients long term treated with Tdf to Etv or Taf. Liver Meeting 2018. San Francisco 2018.","DOI":"10.1016\/j.dld.2018.01.065"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13450"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fliv.14367","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.14367","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/liv.14367","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.14367","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T03:58:08Z","timestamp":1694059088000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/liv.14367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":30,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["10.1111\/liv.14367"],"URL":"https:\/\/doi.org\/10.1111\/liv.14367","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"2019-12-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}